Introduction {#s1}
============

Rhabdomyosarcoma (RMS) presents as a solid tumor that displays characteristics of primitive skeletal muscle ([@bib42]). There are two major histological subtypes, embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS), with ARMS being more aggressive and particularly prone to metastasis ([@bib55]; [@bib49]). At the genomic level, ERMS is characterized by frequent alterations affecting *RAS* signaling, although this still represents a minority of the cases ([@bib50]; [@bib32]; [@bib40]). The defining oncogenic event in ARMS is a t(1;13) or t(2;13) chromosomal translocation in which the *PAX7* or *PAX3* DNA-binding domain, respectively, is fused to the *FOXO1* transactivation domain to create a *PAX3/7-FOXO1* chimeric oncogene ([@bib2]; [@bib14]; [@bib47]; [@bib9]). The *PAX3-FOXO1* fusion is the most prevalent fusion in the disease, and functions as an aberrant transcription factor that is expressed in the nucleus and deregulates gene expression signatures ([@bib10]; [@bib13]; [@bib1]; [@bib28]). This activity is the predominant cellular insult required for transformation.

The *PAX3/7-FOXO1* oncogenes remain intractable to therapeutic targeting, impeding the development of effective precision medicine therapies. Fusions are notoriously difficult to model in animals, hence the limited availability of vertebrate animal models of this disease. Furthermore, there is a narrow understanding of the cellular origin of RMS, making it difficult to define the expression pattern required for tumorigenesis ([@bib17]). Zebrafish are a complementary model system that can address these genetic and cellular issues. Advantages of zebrafish systems are two-fold: (1) they provide insight into the underlying biology of how cancer genes behave in a complex environment and (2) provide a platform for translational drug discovery efforts. Such strengths are intrinsically important for translational models of pediatric disease.

Here, we describe human *PAX3-FOXO1-*driven zebrafish models. We implemented our zebrafish models to provide the appropriate context to understand the behavior of *PAX3-FOXO1* during development and tumorigenesis. The tumor presentation spectrum identified three distinct cellular contexts that are susceptible to transformation, generating insight into basic mechanisms of *PAX3-FOXO1* tumorigenesis and human rhabdomyosarcoma. By applying our zebrafish RMS model, we found a novel *PAX3-FOXO1* target, *her3/HES3. HES3* is a member of the HES family of basic helix-loop-helix transcription factors, which function as direct or indirect transcriptional activators or repressors, thus regulating gene expression and epigenetic identity ([@bib22]). *HES3* is expressed in the developing brain and inhibits differentiation of neural stem cells ([@bib16]). In cancer, *HES3* is expressed in glioblastoma cell culture, and co-localizes with additional markers of stemness in the mouse brain ([@bib43]; [@bib44]; [@bib23]). However, its role as a cooperating gene in *PAX3/7-FOXO1* fusion-positive rhabdomyosarcoma has never been described. Taken together, this model represents a novel strategy to identify new targets and biomarkers in the context of human disease and contributes to our understanding of RMS biology by defining the earliest tumor initiation events.

Results {#s2}
=======

A transgenic zebrafish model of human *PAX3-FOXO1* driven tumorigenesis {#s2-1}
-----------------------------------------------------------------------

To develop a new vertebrate model of *PAX3-FOXO1-*dependent tumorigenesis, we performed a survey of promoters driving *PAX3-FOXO1* expression. These promoters represent ubiquitous (beta actin, CMV, ubiquitin), hematologic (fli1), muscle (unc503), neural crest (mitfa) expression, and a gene trap approach. Selected promoters were chosen because of their relevance in the disease as implicated lineages for the cell of origin or for their capacity to drive *PAX3-FOXO1* at high levels of expression. Further, all promoters had been previously validated as functional in zebrafish, with data from our group underscoring the beta actin promoter as a successful expression system for *EWS-FLI1* transgenic models of Ewing sarcoma ([@bib34]). Human *PAX3-FOXO1* was integrated into the zebrafish genome utilizing the Tol2 transposon-based system and microinjection in a stable mosaic manner. Genomic integration and transgene expression were tracked using a GFP or mCherry fluorescent protein linked to the coding sequence of *PAX3-FOXO1* with a viral 2A sequence ([Figure 1A--D](#fig1){ref-type="fig"}). This results in equimolar expression of both genes on the same mRNA transcript, yet translation as independent proteins. Zebrafish were monitored for up to 19 months. Using this strategy, we identified fusion-oncogene driven tumors first based on gross morphology and then by screening suspected tumors for fluorescent signal.

![Zebrafish models of human *PAX3-FOXO1* tumorigenesis.\
(**A**) Zebrafish were injected at the single-cell stage with mosaic GFP2A-tagged human *PAX3-FOXO1* under the control of various promoters. At 24 hr old, embryos were sorted for GFP expression indicating successful injections (typically 99% GFP+) and were allowed to grow and monitored for up to 19 months to develop tumors. (**B**) Beta-actin-driven *PAX3-FOXO1* primarily produced primitive neuroectodermal tumors in a wild-type genetic background. Shown for all tumors are representative examples with the presentation of gross morphology and GFP expression patterns coupled with a hematoxylin and eosin stain. (**C**) CMV-driven *PAX3-FOXO1* produced rhabdomyosarcoma in the *tp53^M214K/M214K^*-sensitized genetic background. (**D**) Ubiquitin-driven *PAX3-FOXO1* produced an undifferentiated sarcoma in a wild-type genetic background. (**E**) RNAseq data from zebrafish *PAX3-FOXO1* fluorescent tumors showing the number of reads supporting the presence of the human fusion-oncogene. (**F**) Tumor incidence of GFP + tumors detected in BetaActin-GFP2A-*PAX3FOXO1* (*n* = 74) injected zebrafish versus BetaActin-GFP (*n* = 147) injected controls in a wildtype genetic background. (**G**) Tumor incidence of GFP + tumors detected in CMV-GFP2A-*PAX3FOXO1* (*n* = 31) injected zebrafish in a *tp53^M214K^*-sensitizing genetic background.](elife-33800-fig1){#fig1}

Human *PAX3-FOXO1* under the control of different promoters had unique survival and transforming properties suggesting cell-of-origin specificity to oncogenesis. Tested promoters had a negative impact on early survival (up to 30 days of life), but to different extents ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Only a subset of the promoters that were tested induced tumor formation, including the beta actin (9% of injected zebrafish), CMV (16% of injected zebrafish), and ubiquitin (1.8% of injected zebrafish) promoters ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The *fli1*, *unc503*, *mitfa*, and gene trap approach driving *PAX3-FOXO1* were not transforming ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

The three promoters (beta actin, CMV, ubiquitin) that induced *PAX3-FOXO1* transformation in zebrafish had varied requirements for *tp53^M214K^* as a sensitizing mutation. The beta actin promoter driving the expression of *PAX3-FOXO1* is tumorigenic in zebrafish, both in a wildtype and a p53-deficient genetic background. In *tp53* wild-type zebrafish, BetaActin-*PAX3FOXO1* tumors began developing at 3 months of age in 5% of injected zebrafish in the head. Diagnosis of tumors was made by hematoxylin and eosin staining and evaluation by light microscopy. Based on this analysis, the majority of beta-actin-driven *PAX3-FOXO1* zebrafish tumors were consistent with primitive neuroectodermal tumors ([Figure 1B](#fig1){ref-type="fig"}). However, beta-actin-driven *PAX3-FOXO1* injected into the *tp53^M214K/M214K^* mutant resulted in one undifferentiated sarcoma after 412 days.

The CMV promoter restricting *PAX3-FOXO1* expression results in RMS tumors that present in the skeletal muscle of the back. Histological analysis of the zebrafish tumors was consistent with human RMS ([Figure 1C](#fig1){ref-type="fig"}). This was true only in the context of the *tp53^M214K^* mutation, indicating that the *tp53* mutation is sensitizing to and favors RMS. These findings are concordant with the *Pax3-Foxo1* RMS mouse model, in which *Tp53* deletion, or other secondary cooperating mutations are required for RMS development ([@bib25]). Further, patients with Li Fraumeni syndrome develop RMS as part of the spectrum of the human disease ([@bib35]).

The ubiquitin promoter driving *PAX3-FOXO1* generated one undifferentiated sarcoma by 378 days of age in a wild-type genetic background ([Figure 1D](#fig1){ref-type="fig"}). We performed RNA-seq on zebrafish tumors derived from all three promoters (beta actin, CMV, ubiquitin), and detected *PAX3* and *FOXO1* junction spanning reads indicating that human *PAX3-FOXO1* is expressed in fluorescent tumors ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). These data demonstrate that the human fusion-oncogene is transforming in zebrafish when expressed in a variety of cellular contexts and that some, but not all, cellular identities are susceptible to transformation.

The beta actin, CMV, and ubiquitin promoter restricting *PAX3-FOXO1* expression have unique latency, penetrance, and spectrum of tumor development ([Figure 1F--G](#fig1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Tumor incidence curves are shown for the beta actin promoter driving *PAX3-FOXO1* in a wild-type background, and for the CMV promoter driving *PAX3-FOXO1* in the *tp53^M214K/M214K^* mutant background ([Figure 1F--G](#fig1){ref-type="fig"}). Rhabdomyosarcoma only develops in the *tp53^M214K^* background, predominantly with the CMV promoter as compared to the beta actin promoter. Since human *PAX3-FOXO1* is active in zebrafish and produces discrete functional readouts, we next applied our model to identify *PAX3-FOXO1* targets that are engaged during development to induce tumorigenesis.

*PAX3-FOXO1* has a different impact on embryonic development than *PAX3* {#s2-2}
------------------------------------------------------------------------

The *PAX3-FOXO1* fusion-oncogene functions as an aberrant transcription factor due to the *PAX3* DNA-binding domain being linked to the *FOXO1* transactivation domain ([@bib37]; [@bib7]). To identify activity unique to *PAX3-FOXO1* versus the normal *PAX3* transcription factor, we performed a detailed analysis of the functional effects of their expression during zebrafish development. We utilized a mosaic model system, in which plasmid DNAs containing the beta actin promoter driving GFP, or GFP-tagged *PAX3* or *PAX3-FOXO1* were injected into developing zebrafish using the Tol2 transposon system ([Figure 2A](#fig2){ref-type="fig"}). The expression of each construct was tracked using a viral 2A linked fluorescent protein, and mosaic integration of the construct can be observed with fluorescence by 24 hr post-injection ([Figure 2B](#fig2){ref-type="fig"}). During the first three days of life, *PAX3-FOXO1* injected zebrafish exhibited reduced survival as compared to *PAX3* injected zebrafish ([Figure 2C](#fig2){ref-type="fig"}). Furthermore, *PAX3-FOXO1-*induced unique embryonic phenotypes, including cyclopia, which was present in 30% of injected embryos. To address if cyclopia was due to *PAX3-FOXO1* expression, we co-injected GFP2A-*PAX3FOXO1* with a morpholino that targets the expression construct. In this scenario, the morpholino binds the start codon of GFP and inhibits the ribosome's association with the mRNA transcript, thus inhibiting the translation of the GFP-viral2A-*PAX3FOXO1* mRNA. Morpholino activity was tracked by quantifying the reduced number of GFP positive embryos after injection with titrating doses of morpholino ([Figure 2D](#fig2){ref-type="fig"}). Co-injection of *PAX3-FOXO1* and a morpholino that knocks-down GFP-*PAX3-FOXO1* expression eliminated the cyclopia phenotype ([Figure 2D](#fig2){ref-type="fig"}). This is significantly different from the uninjected, GFP injected, and the *PAX3* injected groups, suggesting that *PAX3-FOXO1* is regulating distinct developmental phenotypes.

![*PAX3* and *PAX3-FOXO1* have distinct impacts and tolerance during embryonic development and in adult zebrafish.\
(**A**) Strategy for assessing functional differences of beta-actin-driven *PAX3* and *PAX3-FOXO1* in a vertebrate system. (**B**) Representative images at 24 hr post-fertilization of Uninjected, mCherry2A-*PAX3*, and GFP2A-*PAX3FOXO1-*injected zebrafish. (**C**) Survival curve of Uninjected, GFP2A or mCherry2A injected controls, mCherry2A-*PAX3*, and GFP2A-*PAX3FOXO1*. Error bars represent SE. Log rank test, p\<0.0001 for *PAX3FOXO1* versus all other conditions. (**D**) Embryonic phenotypes scored at 3 days post-injection. \* indicates p\<0.05, for *PAX3 vs PAX3FOXO1*, Fisher's exact test. MO- morpholino. DV- Dorso-Ventral. (**E**) Percentage of GFP + cells from dissociated zebrafish embryos as quantified by fluorescent activated cell sorting (FACS). Error bars represent SD across three independent experiments. \* indicates p\<0.05, two-tailed Student's t-test. (**F**) Adult zebrafish over 3 months of age robustly expressed beta-actin-driven Cherry, GFP, or Cherry2A-*PAX3* and developed normally. Zebrafish injected with BetaActin-GFP2A-*PAX3FOXO1* displayed developmental defects or developed tumors. Arrow denotes GFP + area. The percentage indicates zebrafish with detectable fluorescence at adulthood. (**G**) Hematoxylin and eosin staining showed normal histology of BetaActin-*PAX3* expressing skeletal muscle (sagittal section) at 299 days of age, and abnormal histology of BetaActin-*PAX3FOXO1* epaxial muscle exhibiting dramatic left-right asymmetry (transverse section, asymmetry of left-right epaxial muscle (EM) marked by dotted lines) at 307 days of age. Scale bars, 200 microns. EM- epaxial muscle. (**H**) Representative images from zebrafish embryos injected with GFP2A-*PAX3* and GFP2A-*PAX3FOXO1* that are fixed at 24 hr post-injection and then TUNEL performed (rhodamine). Embryos were counter-stained for GFP to indicate transgene expression. (**I**) Quantification of TUNEL-positive pixels normalized to GFP positive pixels, indicated a higher proportion of *PAX3-FOXO1* cells were undergoing apoptosis. Error bars represent SD, *n* = 6--8 embryos per group, \* indicates p\<0.05, two-tailed Student's t-test.](elife-33800-fig2){#fig2}

This discrepancy between *PAX3-FOXO1* and *PAX3* tolerance was evident at the level of individual cells. To demonstrate this, embryos were injected with beta-actin-driven constructs containing: GFP only, GFP-tagged *PAX3,* or GFP-tagged *PAX3-FOXO1*. Injected zebrafish embryos were allowed to develop for 24 hr, and then dissociated to single-cell suspensions. Fluorescent activated cell sorting (FACS) showed that *PAX3-FOXO1* expression significantly reduced the number of GFP + cells at 24 hr post-fertilization as compared to *PAX3* ([Figure 2E](#fig2){ref-type="fig"}). This reduced viability of *PAX3-FOXO1* + zebrafish was consistent in injected embryos that were raised to adulthood and screened at 3 months of age for detectable fluorescence. In BetaActin-mCherry or GFP fluorescent controls, fluorescence was observed in over 70% of adult zebrafish. In *PAX3-*injected zebrafish, mCherry fluorescence was observed in 32% of adults. We found that only 3% of adult zebrafish had detectable GFP-*PAX3FOXO1* expression with resulting tumor development or asymmetric skeletal muscle ([Figure 2F--G](#fig2){ref-type="fig"}). This was not true for BetaActin-GFP or BetaActin-GFP-*PAX3*, which do not generate tumors or affect normal development or survival.

One explanation for this disappearance of *PAX3-FOXO1* + cells during the course of development is that *PAX3-FOXO1-*injected zebrafish have a significant increase in the number of cells undergoing apoptosis. At 24 hr post-fertilization, TUNEL staining was performed on embryos injected with either GFP-*PAX3* or GFP-*PAX3FOXO1*. These same embryos were counter-stained for GFP to detect the expression levels of their respective transgenes ([Figure 2H](#fig2){ref-type="fig"}). *PAX3-FOXO1-*injected embryos had an increase in the number of TUNEL-positive cells undergoing apoptosis as compared to GFP controls and *PAX3* in wild-type zebrafish ([Figure 2I](#fig2){ref-type="fig"}). Given these data and the propensity to generate RMS we mechanistically evaluated the contribution of *tp53* mutations to early *PAX3-FOXO1-*induced apoptosis ([Figure 1C and G](#fig1){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). We found that *tp53^M214K^* mutant zebrafish embryos are unable to invoke an appropriate response to *PAX3-FOXO1* + cells, resulting in a gross reduction in survival by 3 days of age ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Further, injected CMV-*PAX3FOXO1* + cells are more abundant in *tp53^M214K^* injected mutant zebrafish as compared to their wild-type counterparts by 28 hr post fertilization ([Figure 2---figure supplement 1C--D](#fig2s1){ref-type="fig"}). This significant increase in the number of GFP-*PAX3FOXO1* + cells is coupled with a reduction in the ratio of TUNEL-positive cells, indicating that *tp53^M214K^* mutant zebrafish provide a susceptible environment for *PAX3-FOXO1* + cellular persistence and ultimately tumor development ([Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). This dichotomy of cellular tolerance and apoptosis is not true for wildtype or *tp53^M214K^* mutant zebrafish injected with GFP controls, or GFP-*PAX3* ([Figure 2---figure supplement 1B--G](#fig2s1){ref-type="fig"}). Therefore, at both an organismal and individual cell level, ectopic expression of *PAX3-FOXO1* was less tolerated than the normal *PAX3* gene. Understanding the exact mechanisms for cell tolerance, and defining these discrepancies, could identify the earliest events in RMS transformation or alternatively tumor suppressive responses.

*her3* is a novel developmental target of human *PAX3-FOXO1*. {#s2-3}
-------------------------------------------------------------

Given that *PAX3-FOXO1* is uniquely tumorigenic and has different embryonic effects than *PAX3* this warranted a more thorough study of the specific developmental pathways and targets that were mediating these early outcomes. To accomplish this, we injected zebrafish embryos with DNA expression constructs in which the beta actin promoter drives either a GFP control, or GFP-tagged *PAX3* and *PAX3-FOXO1*, and allowed the embryos to develop for 24 hr. The GFP + cell population from zebrafish embryos was then FACS sorted, total RNA isolated, and microarrays were used to determine differential gene expression signatures. After comparing differentially expressed genes versus the GFP injected control for *PAX3* and *PAX3-FOXO1*, the most highly enriched Gene Ontology (GO) terms indicated that *PAX3* and *PAX3-FOXO1* act as transcription factors ([Figure 3A](#fig3){ref-type="fig"}). This was expected given their well-documented roles in the literature and suggested that the mammalian forms are active in zebrafish systems. Furthermore, DAVID analysis of the enriched genes during normal development suggested that these sorted cell populations identify different subsets of zebrafish embryonic tissues. *PAX3-*positive cells were most indicative of the neural plate, neuroectoderm, or ectoderm, whereas *PAX3-FOXO1* was indicative of a somite, segmental plate, or optic vesicle and immature eye ([Figure 3B](#fig3){ref-type="fig"}). Even though *PAX3* and *PAX3-FOXO1* were injected under the control of the same promoter, cells expressing these genes represent either (1) different cell populations or (2) identical cell populations that have differential transcriptional responses as early as 24 hr post-fertilization.

![*PAX3* and *PAX3-FOXO1* induce distinct gene expression signatures during development, identifying a unique *PAX3-FOXO1* target, *her3*.\
Microarray analysis identified differentially expressed gene signatures in 24 hr old zebrafish FACS sorted embryonic cells that expressed either GFP2A-*PAX3FOXO1* or GFP2A-*PAX3*. (**A**) Gene ontology terms associated with *PAX3* or *PAX3-FOXO1*. (**B**) Embryonic tissues indicative of *PAX3* or *PAX3-FOXO1* gene sets. (**C**) 3D principal components analysis (PCA) of GFP injected controls, *PAX3*, and *PAX3-FOXO1*. (**D**) Intersection of up-regulated genes for *PAX3* and *PAX3-FOXO1* as compared to GFP controls. Uniquely up-regulated *PAX3-FOXO1* target genes were included in downstream analysis only if they possessed a human ortholog. Shown are genes rank ordered based on the fold-change of their expression. (**E**) qRT-PCR of *her3* levels from 24-hr-old zebrafish embryos that are either uninjected controls or injected with GFP, *PAX3*, or *PAX3-FOXO1*. (**F**) qRT-PCR for *PAX3-FOXO1* mRNA levels from 24-hr-old zebrafish embryos injected with *PAX3-FOXO1*, or *PAX3-FOXO1* in combination with a GFP morpholino (GFP MO) that inhibits transgene expression. (**G**) Same samples as in F, but qRT-PCR was performed for *her3*. In E-G the SD is derived from technical triplicates, \* indicates p\<0.05, two-tailed Student's t-test.](elife-33800-fig3){#fig3}

We then performed a principal component analysis (PCA) and found that *PAX3* and *PAX3-FOXO1* expression changes are distinct and show statistical significance in a developmental context ([Figure 3C](#fig3){ref-type="fig"}). This does not contradict the fact that there are a large number of expression changes that are similar between these two transcription factors. Therefore, unique developmental and oncogenic targets of *PAX3-FOXO1* could be ascertained by directly comparing its activity to that of *PAX3*. To determine what these *PAX3-FOXO1* developmental targets might be, we looked at the overlap of induced genes for *PAX3* or *PAX3-FOXO1* versus the GFP controls. We found that *PAX3* and *PAX3-FOXO1* up-regulated 118 shared genes, whereas *PAX3-FOXO1* uniquely induced 529 genes. These 529 genes were of interest because of their association with the fusion-oncogene and potentially tumorigenesis. Of these 529 genes, those without a human ortholog were eliminated from further analysis due to our interest in human disease. This produced a list of primarily developmental transcription factors and homeobox genes, including *her3*, *pax3b*, *dbx1a*, and *lhx1b*. The most highly induced gene unique to *PAX3-FOXO1* expression was *her3*, with a 21-fold increase as compared to the GFP control ([Figure 3D](#fig3){ref-type="fig"}).

We validated that *her3* expression was induced by the human *PAX3-FOXO1* fusion-oncogene in zebrafish by injection of GFP control, *PAX3*, and *PAX3-FOXO1.* Embryos were allowed to develop and then total RNA was isolated from an embryo pool, cDNA transcribed, and a qRT-PCR performed for *her3* expression levels. This analysis indicated that *her3* induction was unique to *PAX3-FOXO1* ([Figure 3E](#fig3){ref-type="fig"}). To verify that the up-regulation of *her3* was dependent on *PAX3-FOXO1*, we co-injected the BetaActin-*PAX3FOXO1* construct with a morpholino that inhibits its early expression by targeting the GFP2A-*PAX3FOXO1* transcript. At 24 hr of age, *PAX3-FOXO1* mRNA levels were measured by qRT-PCR, and co-injection of the morpholino significantly knocked down *PAX3-FOXO1* expression ([Figure 3F](#fig3){ref-type="fig"}). A qRT-PCR was performed on these same samples to evaluate *her3* expression levels, and the results replicated those of *PAX3-FOXO1* ([Figure 3G](#fig3){ref-type="fig"}). These data suggest that *her3* is a novel target of *PAX3-FOXO1 in vivo*, that *her3* is not induced by *PAX3,* and that *her3* expression is dependent on the *PAX3-FOXO1* oncogene.

*HES3,* the human ortholog of *her3,* inhibits in vivo myogenesis and supports inappropriate persistence of *PAX3-FOXO1* + cells {#s2-4}
--------------------------------------------------------------------------------------------------------------------------------

A hallmark of rhabdomyosarcoma is that tumors express early markers along the skeletal muscle lineage such as MYOD1, MYOG and Desmin; however, these tumors fail to terminally differentiate indicating a developmental arrest ([@bib42]; [@bib46]). To determine if this was recapitulated in our zebrafish model, we performed a mosaic co-injection strategy with the beta actin promoter driving GFP-mCherry controls, human *HES3* alone, human *PAX3-FOXO1* alone, or a co-injection of *PAX3-FOXO1* and *HES3* ([Figure 4A](#fig4){ref-type="fig"}). Co-injection of transgenes linked to highly expressed promoters generated mosaic integration that overlaid with muscle proteins such as myosin by 24 hr post-fertilization ([Figure 4B](#fig4){ref-type="fig"}). Based on this observation, zebrafish were injected and allowed to develop for 24 hr, and then fluorescent embryos harvested and total RNA isolated and reverse transcribed for qRT-PCR analysis of muscle marker genes. This survey of temporally stereotyped muscle markers included early markers *myod* and *myog* and terminal muscle differentiation markers *myl1* and *myhz2*. We found that *PAX3-FOXO1* did not affect the mRNA levels of *myod* or *myog*; however, by 24hpf there was a significant reduction in the expression of *myl1* and *myhz2*. Surprisingly, overexpression of *HES3* alone had a similar effect of inhibiting terminal muscle differentiation, indicating that *her3/HES3* contribute to maintaining a more primitive cellular state. Together, *PAX3-FOXO1* and *HES3* had no significant additive effect, suggesting they are functioning in a linear pathway with *her3/HES3* being downstream of *PAX3-FOXO1* ([Figure 4C](#fig4){ref-type="fig"}). Hence, *PAX3-FOXO1* and *HES3* inhibit differentiation in vivo in a vertebrate system via a shared mechanism.

![*HES3* inhibits myogenic differentiation in developing zebrafish and supports persistence of *PAX3-FOXO1-*positive cells.\
(**A**) Zebrafish embryos were injected at the single-cell stage with the beta actin promoter driving GFP-Cherry, GFP-*PAX3FOXO1*, mCherry-*HES3*, or combined mCherry-*HES3* and GFP-*PAX3FOXO1*. Shown are representative embryos at 24 hr post fertilization with indicated transgene expression. (**B**) Representative overlays of zebrafish embryo musculature that were fixed at 24 hr and immunofluorescence performed for myosin (red) and injected genes of interest (GOI; green). (**C**) Pools of *n* = 5 embryos were harvested at 24 hr and markers of myogenesis assessed by qRT-PCR, including *myod*, *myog*, *myl1*, and *myhz2*. SD is derived from technical triplicates. \* indicates significant differences between treatment group and the GFP-mCherry control at a threshold of p\<0.05, two-tailed Student's t-test. (**D**) Representative overlay of images from co-injections of mCherry-*HES3* and GFP-*PAX3FOXO1* from the same embryo at 24 and 72 hr post-fertilization. Images were taken with the same exposure settings and objective. (**E**) Quantification of the number of positive pixels for each embryo imaged at 24 and 72 hr post-fertilization. GFP-positive pixels are plotted after the same settings are applied for imaging and analysis. Each marker represents a single zebrafish embryo at 24 or 72 hr post fertilization, *n* = 6--12 embryos per group. Black bar is the mean, and \* indicates p\<0.05, two-tailed Student's t-test. ns- not significant. (**F**) Same analysis as in E but for mCherry positive pixels.](elife-33800-fig4){#fig4}

The majority of the *PAX3-FOXO1* and *HES3* co-injected cells overlaid indicating that this mosaic system is a powerful model to study the interactions of two genes within the same cell ([Figure 4A and D](#fig4){ref-type="fig"}). Given this capacity, we next determined if *HES3* modified the behavior of GFP-*PAX3FOXO1* + cells during embryogenesis. Zebrafish embryos were co-injected at the single-cell stage with two independent plasmids that were dually integrated into the genome using the Tol2-transposon-based system. The conditions included the beta actin promoter driving: (1) mCherry and GFP, (2) GFP and mCherry-*HES3*, (3) mCherry and GFP-*PAX3FOXO1*, and (4) GFP-*PAX3FOXO1* and mCherry-*HES3*. Both GFP and mCherry images were taken using the same settings at both 24 hr post-fertilization and 72 hr post-fertilization to evaluate the capacity of the cells to survive ([Figure 4D](#fig4){ref-type="fig"}). The number of GFP and mCherry positive pixels were calculated independently and plotted for both timepoints ([Figure 4E--F](#fig4){ref-type="fig"}). Co-injection of *HES3* allowed *PAX3-FOXO1* cells to survive and/or proliferate, with a greater number of GFP-positive pixels and thus *PAX3-FOXO1* positive cells persisting by 72hpf ([Figure 4E](#fig4){ref-type="fig"}). This phenomenon was unique to the co-injection of *HES3 + PAX3FOXO1*, as the number of pixels that were positive between 24hpf and 72hpf for mCherry + GFP*-PAX3FOXO1* was not significantly different. Additionally, the number of mCherry positive pixels from 24hpf to 72hpf was insignificantly different for mCherry-*HES3* + GFP-*PAX3FOXO1* indicating that this observation was not globally applicable, but unique to the persistence of *PAX3-FOXO1* ([Figure 4F](#fig4){ref-type="fig"}). These results suggest that *HES3* promotes a more tolerant cellular environment allowing for survival with expression of the highly toxic *PAX3-FOXO1*.

One hypothesis is that the co-expression of *HES3* allows for *PAX3-FOXO1* expressing cells to circumvent apoptosis. By implementing our CMV injected mosaic zebrafish models, we found that *HES3* overexpression in zebrafish allows for *PAX3-FOXO1*+ cells to either inappropriately persist or divide, resulting in an increased number of observable GFP-*PAX3FOXO1* + pixels by 24 hr post-fertilization ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). We performed TUNEL assays on these same zebrafish embryos and found that *HES3* alone does not induce apoptosis. Further, there is no significant difference in the normalized ratio of TUNEL cells for *PAX3-FOXO1-*injected embryos as compared to *PAX3-FOXO1 + HES3* ([Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}). These data indicate that *PAX3-FOXO1 + HES3* cooperation facilitates *PAX3-FOXO1* + cells to persist during embryogenesis independently of apoptosis inhibition at this timepoint ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

*HES3* inhibits myogenesis in mammalian myoblasts {#s2-5}
-------------------------------------------------

Impaired skeletal muscle differentiation is a signature feature of human RMS tumors. To evaluate how *HES3* is contributing to oncogenesis in fusion-positive RMS, we determined its capacity to inhibit differentiation in mammalian cell culture ([Figure 5A](#fig5){ref-type="fig"}). Stable mouse C2C12 myoblast cell lines were generated by transfection and selection of CMV-*HES3* or CMV-Empty control, and the resulting cell lines were evaluated for overexpression of *HES3* by qRT-PCR ([Figure 5B](#fig5){ref-type="fig"}). Myoblasts were viable with *HES3* overexpression and were next tested to determine if there was a temporal or functional difference in their myogenic capacity. Cells were seeded onto porcine gelatin coated plates and collected at one and 6 days post plating after being exposed to low-serum concentrations and supplemented with insulin to promote fusion. The expression levels of selected genes were evaluated to represent the spectrum of myogenic differentiation, including *MyoD*, *MyoG*, *Myl1*, and *Myh1* ([Figure 5A](#fig5){ref-type="fig"}). By day 6 of differentiation, *MyoD*, *MyoG*, *Myl1*, and *Myh1* exhibited significant inhibition of expression in C2C12-*HES3* overexpressing cells as compared to the C2C12-Empty controls. Moreover, *Myl1* and *Myh1,* which represent terminal muscle differentiation, were the most affected by *HES3* overexpression at fusion day 6, with a 2.9--3.2 fold decrease in expression levels, as compared to a 1.8--1.9 fold decrease observed for *MyoD* and *MyoG* ([Figure 5B](#fig5){ref-type="fig"}).

![*HES3* overexpression inhibits myogenic differentiation of mouse muscle myoblasts.\
(**A**) Schematic of muscle development. Specifically noted are key skeletal muscle transcription factors and proteins assessed in B. Muscle satellite cells that self-renew express *Pax3*/Pax7. During development, they are activated to further differentiate by expression of MyoD, the master muscle regulator, after which they become myoblasts, an intermediate cell type. Myoblasts proliferate and fuse together to form multi-nucleated and contractile myofibers that express structural proteins, such as myosin heavy chain. (**B**) C2C12-Empty and C2C12-*HES3* overexpressing cells were seeded in growth media and after 24 hr exposed to differentiation media. At this point Day 1 of fusion was collected. Following 5 additional days in fusion media the final timepoint was collected. qRT-PCR was performed for *HES3*, and the following muscle marker genes: *MyoD*, *MyoG*, *Myl1*, *Myh1*. SD is derived from technical triplicates. \* indicates p\<0.05, two-tailed Student's t-test. (**C**) C2C12-Empty and C2C12-*HES3* cells were differentiated for five days, fixed, and immunofluorescence performed for Myosin Heavy Chain (MyHC) protein. Cells were counterstained with DAPI to detect DNA. Shown are representative images of the fusion capacity for each condition. (**D**) Quantification of the differentiation capacity of *HES3* overexpressing mouse myoblasts. Plotted are the number of myogenic nuclei (\# of nuclei within a MyHC + cell divided by the total nuclei) with *n* = 3 technical replicates per group ± SD. Experiment was repeated with biological replicates. \* indicates p\<0.05, two-tailed Student's t-test. (**E**) Same data as in D represented as the fusion capacity which focuses on multi-nucleation. The fusion capacity was calculated by including nuclei with *n* \> 3 nuclei per MyHC + cell divided by the total number of nuclei. Plotted is the mean of *n* = 3 technical replicates per group ± SD. Experiment was repeated with biological replicates. \* indicates p\<0.05, two-tailed Student's t-test.](elife-33800-fig5){#fig5}

A decrease in the mRNA expression of markers of muscle identity translated to a reduction in the functional capacity to fuse into multi-nucleated myofibers. C2C12-*HES3* overexpressing cells and C2C12-Empty controls were differentiated in low-serum conditions, and immunofluorescence performed to determine protein expression and localization of myosin heavy chain ([Figure 5C](#fig5){ref-type="fig"}). Both C2C12-Empty and C2C12-*HES3* cells exhibited the capacity to fuse into multi-nucleated myotubes that express myosin heavy chain upon terminal differentiation. However, there was a stark difference in the success of the differentiation. After analyzing the percentage of myogenic nuclei, or the nuclei within a myofiber, there was 2.3X more myogenic nuclei in C2C12-Empty as compared to the C2C12-*HES3* overexpressing cells ([Figure 5D](#fig5){ref-type="fig"}). Furthermore, the fusion index (myogenic nuclei with \> 3 nuclei present per myofiber) indicated a significant reduction in the fusion capacity of *HES3* overexpressing cells ([Figure 5E](#fig5){ref-type="fig"}). HES3 overexpression also modified the kinetics of C2C12 differentiation, with myosin protein being undetectable at day 4 of fusion in C2C12-HES3 overexpressing cells and detectable in C2C12 controls ([Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). These contrasting fusion capacities cannot be fully attributed to a dominant negative effect on MyoD and inhibition of MyoD expression during fusion initiation. In fact, there were comparable levels of MyoD protein at day 3 of C2C12 fusion. By day 9 there is a trend towards decreased MyoD in HES3 overexpressing C2C12 myotubes ([Figure 5---figure supplement 2A--C](#fig5s2){ref-type="fig"}). Hence, HES3 is inhibiting the differentiation process and promoting a more primitive cellular state in mammalian systems.

*HES3* overexpression increases pro-tumorigenic features in cell culture systems {#s2-6}
--------------------------------------------------------------------------------

To determine if *HES3* overexpression confers properties indicative of tumorigenic capacity in cell culture systems, we analyzed *HES3*'s impact on C2C12 mouse myoblasts and human rhabdomyosarcoma cells. We focused on the human cell line, Rh30, which is derived from a bone marrow metastasis of ARMS and contains the *PAX3-FOXO1* fusion ([@bib18]). Stable Rh30 cell lines were generated by transfection and selection of either the CMV-Empty or CMV-*HES3* expression construct. A qRT-PCR verified *HES3* overexpression and that *PAX3-FOXO1* was present ([Figure 6A--B](#fig6){ref-type="fig"}). This overexpression strategy was pursued because of the low levels of baseline *HES3* in Rh30. We examined a panel of rhabdomyosarcoma cell lines and have observed low *HES3* levels by RNAseq, and no detectable endogenous HES3 protein expression with commercially available antibodies (data not shown). To determine if *HES3* modified the proliferation kinetics of Rh30, cells were plated at a low density and timepoints evaluated from days 1 to 6. We found that in this context *HES3* accelerated the cellular accumulation of Rh30 ([Figure 6C](#fig6){ref-type="fig"}). Additionally, overexpression of *HES3* modified the expression of a panel of genes implicated in metastasis and more aggressive disease. Notably, there was \> 300 fold down-regulation of Missing in Metastasis (*MTSS1*), and an up-regulation of matrix metallopeptidases 3 and 9 (*MMP3* and *MMP9*) ([Figure 6D](#fig6){ref-type="fig"}).

![*HES3* overexpression promotes pro-tumorigenic features in *PAX3-FOXO1* RMS patient cells and mouse myoblasts.\
(**A**) Rh30 cells stably express CMV-*HES3* as evaluated by qRT-PCR. SD is derived from technical triplicates. (**B**) *PAX3-FOXO1* levels were assessed by qRT-PCR on the same samples in A. SD is derived from technical triplicates. (**C**) Cells were seeded at a low density and timepoints taken on Days 1, 3, 5, 6 to assess cellular accumulation. At each timepoint, cells were fixed and stained with crystal violet. Plotted is the absorbance from each timepoint with *n* = 4 technical replicates ± SE. Each experiment was repeated two times with biological duplicates. (**D**) qPCR array of metastasis associated genes for Rh30-*HES3* versus Rh30-Empty. Red indicates \> 2-fold change above the mean, blue indicates \> 2-fold change below the mean. (**E**) C2C12 cells stably expressed CMV-Empty or CMV-*HES3*, and qRT-PCR confirmed *HES3* overexpression. SD is derived from technical triplicates. (**F**) C2C12 cells were seeded at a low density and timepoints taken on Days 1--6 to assess cellular accumulation. At each timepoint, cells were fixed and stained with crystal violet. Plotted is the absorbance from each timepoint with *n* = 4 technical replicates ± SD. Each experiment was repeated two times with biological duplicates. (**G**) Soft-agar colony formation assay was performed over 30 days for C2C12-Empty versus C2C12-*HES3*. Each data point is the mean of three images per well, across six technical replicates. Black bar indicates the mean. (**H**) qPCR array of rhabdomyosarcoma associated genes for C2C12-*HES3* versus C2C12-Empty. Red indicates \> 2-fold change above the mean, blue indicates \> 2-fold change below the mean. In all panels \* indicates p\<0.05, two-tailed Student's t-test.](elife-33800-fig6){#fig6}

Complementary results were obtained when C2C12 cells were transfected with either an empty control vector or CMV-*HES3*. Stable C2C12-*HES3* cells overexpressed *HES3* as compared to the C2C12-Empty control ([Figure 6E](#fig6){ref-type="fig"}). *HES3* was then evaluated for its ability to modulate cellular accumulation. *HES3* significantly accelerated the growth kinetics of C2C12 cells when plated at sub-confluent levels over the course of 6 days ([Figure 6F](#fig6){ref-type="fig"}). These same cells were plated in suspension in soft agar and cultured for one month to determine the colony formation capacity. *HES3* overexpression significantly increased the number of colonies that formed ([Figure 6G](#fig6){ref-type="fig"}). This is complemented by data indicating that *HES3* alters the expression of genes that are *PAX3-FOXO1* direct targets or whose expression is modified by *PAX3-FOXO1*; including, *MyoG*, *Igf2*, and *Hoxc6* ([Figure 6H](#fig6){ref-type="fig"}) ([@bib28]; [@bib31]). Potentially, *HES3* is acting as a transcriptional activator and repressor, consistent with its role in normal development.

*HES3* is overexpressed in patient tumors, predicts reduced survival, and identifies potential therapeutic targets {#s2-7}
------------------------------------------------------------------------------------------------------------------

We evaluated the clinical significance of *HES3* by determining *HES3* expression levels in human RMS tumors. We analyzed RNA-Seq and HuEx array data from three independent RMS tumor cohorts, together representing the largest collection of over 200 sequenced RMS tumors ([@bib8]; [@bib48]). We found that *HES3* had higher expression levels in fusion-positive RMS as compared to fusion-negative RMS ([Figure 7A--C](#fig7){ref-type="fig"}). Significantly, in RMS patients, the overexpression of *HES3* is associated with reduced overall survival in *PAX3/7-FOXO1* fusion-positive RMS patients, but not in fusion-negative RMS patients ([Figure 7D](#fig7){ref-type="fig"}). RMS tumors from [@bib48] were evaluated for *HES3* expression levels, and then differentially expressed genes expounded between *HES3* high and low tumors to identify molecular targets with potential translational benefit. A subset of clinically relevant kinases and molecular targets was identified as being concordantly overexpressed with *HES3*; namely, *FGFR4, ALK*, and *PARP1* ([Figure 7E](#fig7){ref-type="fig"}). Taken together, these data are consistent with our results showing that *her3*/*HES3* is a *PAX3-FOXO1* target, and that *HES3* contributes to a more aggressive phenotype in rhabdomyosarcoma.

![*HES3* is overexpressed in fusion-positive RMS patient tumors, predicts reduced overall survival, and identifies potential therapeutic targets.\
*HES3* expression levels determined in fusion-positive ARMS versus fusion-negative ARMS/ERMS. (**A**) RNAseq data from [@bib48] . (**B**) HuEx data from Triche T, Skapek S; GEO: Accession Number GSE114621. (**C**) RNAseq data from [@bib8]. p-Values were calculated based on two-tailed Student's t-test (**D**) Survival curve of fusion-positive ARMS in the context of *HES3* expression status (*n* = 7 per group). *HES3* expression is derived from the HuEx data presented in B. (**E**) RMS patient tumors from [@bib48] were stratified based on high (FPKM \> 1, *n* = 25) or low (FPKM \< 1, *n* = 80) *HES3* expression and these subsets evaluated for the most differentially expressed genes (FDR \< 0.005). Listed are a subset of kinases or other druggable targets that are up-regulated (red) or down-regulated (blue) in the context of *HES3* overexpression. Genomic datasets from analysis of human subjects are dbGaP controlled-access data, available to users submitting an approved data access request through the dbGaP Authorized Access System (<https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login>.](elife-33800-fig7){#fig7}

Discussion {#s3}
==========

Despite the identification of the primary oncogenic driver *PAX3/7-FOXO1* over 20 years ago, there have been few changes to the primary treatment and prognosis of the disease ([@bib2]; [@bib14]; [@bib47]; [@bib9]). Developing complementary ARMS animal models will aid in the understanding of disease biology and identify new therapeutic avenues. Zebrafish ARMS models provide a relevant vertebrate developmental context with experimental advantages such as lineage tracing of the ARMS cell of origin, identifying *PAX3-FOXO1* transcriptional targets, and providing a platform for a high-throughput drug screens. Here, we describe a genetic zebrafish model of human disease, in which the human fusion-oncogene, *PAX3-FOXO1*, is mosaically integrated into the zebrafish genome. We found that the human fusion is oncogenic in zebrafish under the control of the beta actin, CMV, and ubiquitin promoters, resulting in PNETs, RMS, and histologically undifferentiated sarcoma. Surprisingly, *PAX3-FOXO1* transformation capacity is not limited to myogenic cells, reflecting the lineage specific control of *PAX3* which is relevant in the developing brain and muscle. Specific lineages that have been postulated as possible RMS tissues of origin, such as endothelial, neural crest and differentiated muscle (represented here by the *fli1*, *mitfa*, and *unc503* promoters) did not develop tumors, highlighting the requirement for high-expressing ubiquitous promoters in this model. Whereas in patient genomic data, *PAX7-FOXO1* undergoes copy number gain to increase its expression levels, this is not the case for *PAX3-FOXO1*. Likely, *PAX3-FOXO1* must increase its expression level for transformation via transcriptional upregulation ([@bib3]). To achieve these higher levels of transcription and transformation, we opted to utilize high-level promoters. This threshold was likely not reached with the *fli1*, *mitfa,* and *unc503* endogenous promoters, or, the lineages and/or temporal kinetic of transgene expression are not relevant to the disease.

In our zebrafish model, the relevant *PAX3-FOXO1* RMS cell type is supportive of CMV-mediated gene expression and requires a *tp53* mutation. These observations are substantiated by the mouse *Pax3-Foxo1* RMS model, in which deletion of *Tp53* or *Cdkn2a* is required for tumor development ([@bib25]). In our zebrafish ARMS model, *tp53* mutations allow for *PAX3-FOXO1* + cells to survive during embryogenesis by inhibiting apoptosis resulting in later tumor formation ([Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[2](#fig2s2){ref-type="fig"}). This may represent a unique necessity in animal models as both fusion-positive RMS vertebrate models of the disease require that *tp53* is mutant or lost. In zebrafish, beta-actin-driven *PAX3-FOXO1* is sufficient for tumorigenesis, providing a cleaner background for its functional assessment and greater conservation with the genetics of the human disease. One possible explanation is that zebrafish do not have p14 ARF orthologs, making it an unique model to understand the function of the fusion alone. Therefore, we pursued embryonic analyses of *PAX3-FOXO1* function using both the beta actin and CMV promoters due to their tumorigenic effects and unique genetic requirements. We found by performing analogous studies with BetaActin-*PAX3FOXO1* and CMV-*PAX3FOXO1* that these expression constructs behaved comparably in an embryonic environment ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[2](#fig2s2){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}--[2](#fig4s2){ref-type="fig"}). Focusing on robust and conserved early oncogenic mechanisms that are consistent across multiple promoter models limited the possibility of artifactual observations.

By studying *PAX3-FOXO1* signaling in a complex developmental context, we identified a novel fusion-positive RMS biomarker, *her3*/*HES3*, that predicts more aggressive disease. *her3* is a transcription factor that contains a DNA-binding domain, an orange domain, and a tetrapeptide motif at the C terminus ([@bib15]). In zebrafish and mouse models, *her3* is expressed in the neuroepithelial stem cells of the neural plate and inhibits their premature differentiation ([@bib16]). The human ortholog of *her3, HES3,* is a member of the basic helix-loop-helix (bHLH) transcription factor family, which includes *MYOD1* and *MYOG*, that are known to be transcriptionally targeted by *PAX3-FOXO1* (14, 33). *HES3* acts as both a transcriptional repressor and activator, by indirectly or directly influencing transcription depending on its sub-cellular localization. *PAX3-FOXO1* regulation of *HES3* is likely indirect. Chip-seq data from rhabdomyosarcoma cell culture indicates that *PAX3-FOXO1* does not bind the *HES3* promoter; however, these results may differ in a dynamic developmental context ([@bib7]). Copy number analysis of fusion-positive patient RMS tumors finds no amplification of *HES3*, indicating up-regulation is at the transcriptional level. Our data suggest that *PAX3-FOXO1* and *HES3* function linearly, with *HES3* being downstream of *PAX3-FOXO1*. The exact mechanisms of regulation will be addressed in future studies.

*HES3* contributes to more aggressive disease in patients when overexpressed in the context of the *PAX3-FOXO1* fusion, likely by a multi-variate platform of: (1) inhibiting terminal muscle differentiation, (2) modifying cellular plasticity to make cells that acquire the *PAX3-FOXO1* fusion more tolerant of its expression, and (3) inducing additional transcriptional changes. *PAX3-FOXO1* induction of *HES3* expression in a mesodermal lineage is ectopic, and *HES3* plays no known role in normal somitogenesis or myogenesis. We have found that mis-expression of *HES3* during embryonic development inhibits muscle differentiation. We note that *HES3* allows for *PAX3-FOXO1* cells to inappropriately persist during embryogenesis independently of inhibiting apoptosis. In human fusion-positive RMS, which typically lack *TP53* mutations ([@bib48]), *HES3* overexpression could represent an alternative mechanism to facilitate *PAX3-FOXO1* + cell persistence and tumor initiation events. This role for *HES3* promoting *PAX3-FOXO1* + embryonic persistence is suggestive of *HES3*'s capacity in normal development to alter cellular plasticity. *PAX3-FOXO1* in combination with *HES3* could be challenging the epigenetic identity of mutated cells. Finally, we provide evidence that *HES3* may induce a more aggressive and/or metastatic program in *PAX3-FOXO1* + patient RMS, including the down-regulation of *MTSS1* and up-regulation of *MMP3* and *MMP9* (34, 35). Previous studies indicate that *MTSS1* is a target of the *PAX3-FOXO1* fusion ([@bib12]); therefore, the modification of *MTSS1* expression, and additional genes integral in cell invasion could occur in part through *PAX3-FOXO1* induction of *HES3*. Most significantly, stratifying patient tumor data between *HES3* high and low expressing RMS elucidated translational molecular targets with immediate potential applications in the clinic such as co-expression of *FGFR4*, *ALK*, and *PARP1*.

Overall, this new *PAX3-FOXO1* zebrafish model of rhabdomyosarcoma identifies *her3*/*HES3* as a mediator of tumorigenesis. Further application of this model determined mechanisms of *PAX3FOXO1/HES3* cooperation that result in more aggressive disease. Given the strengths of the zebrafish system, we can now apply it for drug screening and repurposing efforts. We envision the utility of our zebrafish *PAX3-FOXO1* RMS model being applied for transplant experiments, where generated tumors can be propagated and grafted into adult zebrafish and in developing zebrafish embryos for further study. Zebrafish embryos containing *PAX3-FOXO1* + tumor cells can be exposed to single or combinations of small molecules that effectively couple efficacy for tumor elimination with toxicity data in a vertebrate whole animal model. Additionally, zebrafish cancer models are a complementary approach to ongoing sequencing efforts of patient tumors. The functional significance of cooperating genetic mutations can be determined quickly and robustly. In our study, we find that human *PAX3-FOXO1* and *HES3* are active in zebrafish, and that biomarkers identified in this system are relevant in the human disease. We anticipate that additional application of this new *PAX3-FOXO1* driven tumor model will elucidate novel tumorigenic mechanisms and avenues for treatment.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                     Source or reference           Identifiers               Additional information
  (species) or resource                                                                                                
  ---------------------------- ------------------------------- ----------------------------- ------------------------- -----------------------------------------------------------------------
  Gene (*Homo sapiens*)        *HES3*                          NA                            NM_001024598              

  Gene (*Homo sapiens*)        *PAX3-FOXO1*                    PMID:8275086;\                NM_181457;\               exons 1--7 of NM_181457\
                                                               PMID:8221646                  NM_002015.3               fused to exons 2--3 of\
                                                                                                                       NM_002015.3

  Gene (*Mus musculus*)        *Pax3*                          NA                            NM_008781                 

  Gene (*Danio rerio*)         *her3*                          NA                            NM_131080                 

  Strain, strain\              AB Wildtype                     Zebrafish International\      ZIRC:ZL1                  <https://zebrafish.org/fish/lineAll.php>
  background\                                                  Resource Center (ZIRC)                                  
  (*Danio rerio* AB)                                                                                                   

  Strain, strain\              AB\\TL Wildtype                 NA                                                      Cross of AB and TL
  background\                                                                                                          
  (*Danio rerio* AB/TL)                                                                                                

  Strain, strain\              TL Wildtype                     ZIRC                          ZIRC:ZL86                 <https://zebrafish.org/fish/lineAll.php>
  background\                                                                                                          
  (*Danio rerio* TL)                                                                                                   

  Strain, strain\              WIK Wildtype                    ZIRC                          ZIRC:ZL84                 <https://zebrafish.org/fish/lineAll.php>
  background\                                                                                                          
  (*Danio rerio* WIK)                                                                                                  

  Strain, strain\              *tp53^M214K^* mutant            PMID:15630097;\               ZIRC:ZL1057               <https://zebrafish.org/fish/lineAll.php>
  background\                                                  available from ZIRC                                     
  (*Danio rerio*\                                                                                                      
  *tp53^M214K^* mutant)                                                                                                

  Genetic reagent              Tol2 transposase mRNA           PMID:16959904                                           Injected at 50 ng/uL

  Cell line\                   C2C12                           ATCC                          ATCC:CRL-1772             Maintained in DMEM + 10%\
  (*Mus musculus*)                                                                                                     FBS+1X Antimycotic-Antibiotic

  Cell line\                   Rh30                            ATCC                          ATCC:CRL-2061             Maintained in\
  (*Homo sapiens*)                                                                                                     RPMI-1640 + 10%\
                                                                                                                       FBS+1X Antimycotic-Antibiotic

  Transfected\                 CMV-HES3\                       Origene                       Origene:RC224630          
  construct (*Homo sapiens*)   (MYC and FLAG tagged)                                                                   

  Transfected\                 CMV-Empty                       this paper                                              *HES3* excised using EcoR1\
  construct (NA)                                                                                                       and Mlu1 and re-ligated

  Antibody                     MF20 (mouse monoclonal)         Developmental Studies\        DSHB:MF20c                1:40 in cells, 1:100 in\
                                                               Hybridoma Bank                                          zebrafish embryo whole\
                                                                                                                       mounts, 1:1000 Western blot

  Antibody                     alpha-Tubulin DM1A\             Cell Signaling                Cell Signaling:3873       1:1000 dilution
                               (mouse monoclonal)                                                                      

  Antibody                     MyoD 5.8A\                      Thermo                        Thermo:MA5-12902          1:1000 dilution
                               (mouse monoclonal)                                                                      

  Antibody                     MYC 71D10\                      Cell Signaling                Cell Signaling:2278       1:1000 dilution
                               (rabbit monoclonal)                                                                     

  Antibody                     GFP (rabbit polyclonal)         MBL International\            MBL:598                   1:1000 dilution
                                                               Corporation                                             

  Antibody                     GFP-488 (rabbit\                Thermo                        Thermo:A-21311            1:500 dilution
                               polyclonal)                                                                             

  Antibody                     Alexa 488 or 594\               Thermo                                                  1:500 dilution
                               secondaries                                                                             

  Antibody                     HRP conjugate\                  BioRad                                                  1:20000 dilution
                               secondaries                                                                             

  Other                        DAPI stain (ProLong\            Thermo                        Thermo:P36931             
                               Gold Antifade mounting\                                                                 
                               media with DAPI)                                                                        

  Recombinant\                 p5E beta actin                  PMID:17937395                                           
  DNA reagent                                                                                                          

  Recombinant\                 p5E cmv                         PMID:17937395                                           
  DNA reagent                                                                                                          

  Recombinant\                 p5E mcs                         PMID:17937395                                           
  DNA reagent                                                                                                          

  Recombinant\                 p5E ubi                         PMID:21138979;\               Addgene:27320             
  DNA reagent                                                  available from Addgene                                  

  Recombinant\                 p5E unc503                      PMID:23444339;\               Addgene:64020             
  DNA reagent                                                  available from Addgene                                  

  Recombinant\                 p5E fli1a                       PMID:17948311;\               Addgene:31160             
  DNA reagent                                                  available from Addgene                                  

  Recombinant\                 p5E mitfa                       James Lister;\                Addgene:81234             
  DNA reagent                                                  available from Addgene                                  

  Recombinant\                 pmE beta globin\                PMID:15239961                                           
  DNA reagent                  splice acceptor                                                                         

  Recombinant\                 pmE GFP2A                       PMID:17941043                                           
  DNA reagent                                                                                                          

  Recombinant\                 pmE mCherry2A                   PMID:17941043                                           
  DNA reagent                                                                                                          

  Recombinant\                 p3E *PAX3-FOXO1*                this paper                                              attb2r/attb3 sites added\
  DNA reagent                                                                                                          with primers in\
                                                                                                                       [Supplementary file 3](#supp3){ref-type="supplementary-material"} by\
                                                                                                                       high-fidelity PCR

  Recombinant\                 p3E *Pax3*                      this paper                                              attb2r/attb3 sites added\
  DNA reagent                                                                                                          with primers in\
                                                                                                                       [Supplementary file 3](#supp3){ref-type="supplementary-material"} by\
                                                                                                                       high-fidelity PCR

  Recombinant\                 p3E *HES3*                      this paper                                              attb2r/attb3 sites added\
  DNA reagent                                                                                                          with primers in\
                                                                                                                       [Supplementary file 3](#supp3){ref-type="supplementary-material"} by\
                                                                                                                       high-fidelity PCR

  Recombinant\                 p3E SV40 late poly A            PMID:17937395                                           
  DNA reagent                                                                                                          

  Recombinant\                 p3E 2A-mCherry                  PMID:23462469;\               Addgene:26031             
  DNA reagent                                                  available from Addgene                                  

  Recombinant\                 pDONRP2R-P3 (3′ donor\          Invitrogen                    Invitrogen:pDONR\         Used to generate\
  DNA reagent                  vector; attP2R-P3\                                            P2R-P3                    p3E\'s from this paper
                               flanking chlor/ccdB cassette)                                                           

  Recombinant\                 pDestTol2pA2\                   PMID:17937395                                           
  DNA reagent                  destination vector                                                                      

  Recombinant\                 BetaActin-GFP2A-pA              this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 BetaActin-mCherry2A-pA          this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 BetaActin-GFP2A-\               this paper                                              Generated by\
  DNA reagent                  2AmCherry                                                                               Gateway Cloning

  Recombinant\                 BetaActin-mCherry2A-*Pax3*      this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 BetaActin-GFP2A-*Pax3*          this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 BetaActin-mCherry2A-*HES3*      this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 BetaActin-GFP2A-*PAX3FOXO1*     this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 CMV-GFP2A-pA                    this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 CMV-mCherry2A-pA                this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 CMV-GFP2A-*Pax3*                this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 CMV-mCherry2A-*HES3*            this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 CMV-GFP2A-*PAX3FOXO1*           this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 ubi-GFP2A-*PAX3FOXO1*           this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 mitfa-GFP2A-*PAX3FOXO1*         this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 fli1-GFP2A-*PAX3FOXO1*          this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 unc503-GFP2A-*PAX3FOXO1*        this paper                                              Generated by\
  DNA reagent                                                                                                          Gateway Cloning

  Recombinant\                 SpliceAcceptor-\                this paper                                              Generated by\
  DNA reagent                  GFP2A-*PAX3FOXO1*                                                                       Gateway Cloning

  Sequence-based\              GFP Morpholino                  Gene Tools                    Gene Tools:\              (5\' ACAGCTCCTCGCCC\
  reagent                                                                                    GFP Morpholino            TTGCTCACCAT 3\')

  Commercial assay\            ApopTag Red In Situ\            Millipore                     Millipore:S7165           
  or kit                       Apoptosis Detection Kit                                                                 

  Commercial assay\            Affymetrix Zebrafish\           Affymetrix                    Affymetrix:901802         
  or kit                       Gene 1.1 ST Array strip                                                                 

  Commercial assay\            M384 Rhabdomy\                  BioRad                        BioRad:M384\              
  or kit (*Mus musculus*)      osarcoma 384 well panel                                       Rhabdomyosarcoma          

  Commercial assay\            H384 Tumor Metastasis\          BioRad                        BioRad:H384 Tumor\        
  or kit (*Homo sapiens*)      (SAB Target List) 384\                                        Metastasis (SAB Target\   
                               well panel                                                    List)                     

  Chemical\                    Geneticin (G418)                Thermo                        Thermo:10131027           Select at 1 mg/mL
  compound, drug                                                                                                       

  Software, algorithm          ImageJ                          <http://imageJ.nih.gov/ij>                              

  Software, algorithm          GraphPad Prism 7.0 c            <https://www.graphpad.com>                              

  Software, algorithm          Rv3.3.1                         <https://www.R-project.org>                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Zebrafish Husbandry {#s4-1}
-------------------

*Danio rerio* were maintained in an Aquaneering aquatics facility according to industry standards. Vertebrate animal work is accredited by AALAC and overseen by the UT Southwestern IACUC committee. AB, WIK, TL, and AB/TL were the wild-type lines used and were obtained from the Zebrafish International Resource Center (<https://zebrafish.org>). The *p53* mutant line, *tp53^M214K^,* was a kind gift from Tom Look ([@bib5]).

Plasmids and cloning {#s4-2}
--------------------

Mouse *Pax3* coding sequence and human *PAX3-FOXO1* coding sequence was a gift from Steve Skapek. The *HES3* coding sequence with a MYC-DDK C-terminal tag was obtained from ORIGENE (RC224630). *Pax3*, *PAX3-FOXO1*, and *HES3* were cloned into the Gateway expression system (Thermo) by adding 5' and 3' ATT sites (attb2r/attb3) with primers and high-fidelity PCR (Thermo; [Supplementary file 3](#supp3){ref-type="supplementary-material"}). Purified PCR products were cloned into a 3'entry clone using the described protocol ([@bib26]). The tol2 kit beta actin promoter, cmv promoter, multiple cloning site, hsp70l promoter, 3' SV40 late poly A signal construct, and pDestTol2pA2 destination vector were used for construct generation and expression in zebrafish ([@bib30]). The ubi promoter was a kind gift from Len Zon (Addgene \#27320) ([@bib41]), the unc503 promoter from Peter Currie (Addgene \#64020) ([@bib4]), the fli1 promoter and 3' entry 2A-mCherry from Nathan Lawson (Addgene \#31160 and \#26031) ([@bib53]; [@bib54]), and the mitfa promoter from James Lister (Addgene \#81234). Middle entry beta globin intron and splice acceptor was from Koichi Kawakami ([@bib24]). The plasmids containing a GFP or mCherry viral 2A sequence were a gift from Steven Leach ([@bib45]), and were sub-cloned into a middle entry Gateway expression system. Tol2 mRNA was synthesized from pCS2FA-transposase which was from Koichi Kawakami ([@bib52]). The constructs generated and utilized in the described studies include: BetaActin-GFP2A-pA, BetaActin-mCherry2A-pA, BetaActin-GFP2A-2AmCherry, BetaActin-mCherry2A-*Pax3*, BetaActin-GFP2A-*Pax3*, BetaActin-mCherry2A-*HES3*, BetaActin-GFP2A-*PAX3FOXO1*, CMV-GFP2A-pA, CMV-mCherry2a-pA, CMV-GFP2A-*Pax3*, CMV-mCherry2A-*HES3*, CMV-GFP2A-*PAX3FOXO1*, ubi-GFP2A-*PAX3FOXO1*, mitfa-GFP2A-*PAX3FOXO1*, fli1-GFP2A-*PAX3FOXO1*, unc503-GFP2A-*PAX3FOXO1*, SpliceAcceptor-GFP2A-*PAX3FOXO1*.

Zebrafish embryo injections {#s4-3}
---------------------------

Zebrafish were injected at the single-cell stage with equimolar ratios of the described DNA constructs. Injection mixes contained 50 ng/µL Tol2 transposase mRNA, 25 or 50 ng/µL of BetaActin-GFP2A-*PAX3FOXO1* or CMV-GFP2A-*PAX3FOXO1*, and equivalent molar amounts of comparative plasmid DNA, 0.1% phenol red, and 0.3X Danieau's buffer. In knock-down experiments, 300 µM of GFP morpholino (5' ACAGCTCCTCGCCCTTGCTCACCAT 3'; Gene Tools), was added to the injection mixes in combination with the plasmid DNA.

Zebrafish embryo survival and embryonic cellular persistence {#s4-4}
------------------------------------------------------------

For survival analysis of embryos, the total number of injected fish was counted, and then the resulting dead or alive embryos subsequently determined at 24, 48, and 72 hpf. Survival curves were plotted using GraphPad Prism 7.0 c (La Jolla, CA). For cellular persistence analysis during embryogenesis, embryos were injected at the single-cell stage with equimolar amounts of plasmid DNA and Tol2 transposase mRNA. At 24 hr post fertilization zebrafish embryos were dechorionated, and then individually imaged at 24 and 72 hr for GFP and mCherry expression using the exact same settings. In ImageJ, the positive pixel threshold was determined and then applied to quantify the number of GFP or mCherry-positive pixels for each embryo.

Zebrafish embryo FACS sorting {#s4-5}
-----------------------------

For FACS sorting of GFP-positive zebrafish cells, zebrafish embryos were injected with purified DNA constructs and transposon mRNA at the single-cell stage and allowed to develop for 24 hr, after which they were deyolked and dissociated to single cells ([@bib38]). Using a MoFlo Cell Sorter (Beckman Coulter Life Sciences) live cells were gated, and then GFP + zebrafish cells were sorted out and collected in 1X Phosphate Buffered Saline (Thermo) on ice. Total RNA was immediately isolated using the RNeasy Microkit (Qiagen) and its integrity confirmed by Nanodrop on a spectrophotometer and a Bioanalyzer RNA Nanochip (Agilent). Total RNA was utilized for the Zebrafish Affymetrix Gene 1.1 Microarray strips which was run in-house.

Zebrafish tumor collection, processing for RNA/DNA and histology, and tumor incidence {#s4-6}
-------------------------------------------------------------------------------------

Zebrafish with tumors were humanely euthanized and screened under a Nikon SMZ25 fluorescent stereomicroscope to detect the fluorescent protein indicative of transgene expression. Fresh GFP + tumor tissue was resected and snap frozen in liquid nitrogen. Frozen tissue was subjected to DNA isolation with the DNeasy Kit (Qiagen) or total RNA isolation using the RNeasy Microkit (Qiagen). The remaining tumor specimen was placed in histology cassettes and fixed in 4% paraformaldehyde/1XPBS for 48 hr at 4°C (Fisher). They were then de-calcified in 0.5M EDTA for 5 days and mounted in paraffin blocks for microtome sectioning. Hematoxylin and eosin staining was performed on de-paraffinized slides. For tumor incidence curves, zebrafish were injected and then only those surviving past 30 days of age were included in the analysis. All zebrafish were screened under the fluorescent microscope to determine if they were GFP positive or negative. Zebrafish without GFP fluorescence were considered to be negative for transgene-dependent tumor formation. Zebrafish that were GFP positive were collected as described earlier, and the presence of malignancies confirmed by hematoxylin and eosin staining and visual review by a pathologist.

Detection of apoptosis in whole-mount zebrafish embryos {#s4-7}
-------------------------------------------------------

Injected zebrafish embryos were fixed at 24 hr post fertilization in 4% paraformaldehyde/1XPBS for 24 hr at 4°C or for 2 hr at room temperature in scintillation vials. TUNEL staining was performed using the ApopTag Red In Situ Apoptosis Detection Kit (Millipore). A GFP counter-stain was performed with an anti-GFP antibody at 1:1000 (MBL International Corporation) and an Alexa Fluor 488 goat anti-rabbit IgG secondary (H + L) at 1:500 (Thermo), or an anti-GFP polyclonal antibody directly conjugated to Alexa Fluor 488 at 1:500 (Thermo). Images for rhodamine/GFP were taken using the same settings across embryos on a Nikon SMZ25 fluorescent stereomicroscope, and number of positive pixels in each embryo determined and analyzed in ImageJ.

Microarray {#s4-8}
----------

Gene expression signatures of injected zebrafish embryos were compared for GFP controls, *Pax3*, or *PAX3-FOXO1* using the Affymetrix Zebrafish Gene 1.1 ST Array strip (Cat \#901802). Each sample was run with technical triplicates. Microarray analyses were conducted using the R v3.3.1 environment (R core Team 2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (<https://www.R-project.org>). Expression profiles were extracted and normalized using Robust Microarray Average ([@bib21]). The intersection of statistically significant up-regulated genes for *Pax3* and *PAX3-FOXO1* conditions as compared to an injected GFP control was determined. Significance was assessed using a Welsh Two Sample t-tests. Genes unique to *PAX3-FOXO1* expression were eliminated if they did not contain a human ortholog (based on NBCI HomoloGene build 68 database), and genes were then rank ordered and prioritized based on fold change. Genes with statistically significant expression changes were analyzed using DAVID (<https://david.ncifcrf.gov/>) ([@bib19]; [@bib20]) to identify enriched Gene Ontology (GO) terms (<http://www.geneontology.org/>).

RNA sequencing {#s4-9}
--------------

Approximately 2 µg of total RNA was utilized for poly-A RNA enrichment and subsequent library preparation. Sequencing was performed on the Illumina NextSeq 500 Sequencing System with 2 × 75 bp paired end reads. For RNA-seq data, adapter removal and quality-filtering was conducted by Cutadapt ([@bib39]). Alignment to the reference zebrafish genome, build GRCz10, was performed by Bowtie2 ([@bib33]), an ultrafast and memory-efficient tool for aligning sequencing reads to long reference sequences. TopHat2 ([@bib29]) was used for alignment. De novo assembly of reads into transcripts (including mRNA, lincRNA, and many other RNA species) and differential expression analysis were performed by Cufflinks and Cuffdiff ([@bib51]). To detect the human *PAX3-FOXO1* fusion, we realigned all reads to the known junction sequence within *PAX3-FOXO1* fusion, which is shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. To reduce false positives, we required that (1) junction-spanning reads should contain no mismatch with known *PAX3-FOXO1* junction sequence and (2) junction-spanning reads with less than 6 bp matches on either gene was discarded, as suggested by an earlier study ([@bib36]).

Immunofluorescence {#s4-10}
------------------

In cells, the MF20 primary antibody was utilized for detection of myosin heavy chain at a dilution of 1:40 (Developmental Studies Hybridoma Bank; DSHB) in combination with an Alexa Fluor 488 goat anti-mouse IgG (H + L) secondary antibody at a dilution of 1:500 (Thermo). DNA was detected using ProLong Gold Antifade mounting media with DAPI (Thermo). MF20 staining in cells was performed as in [@bib27]. In zebrafish embryo whole mounts, the MF20 antibody was used for the detection of myosin at a concentration of 1:100 in combination with an anti-GFP polyclonal antibody directly conjugated to Alexa Fluor 488 at 1:500 (Thermo). The secondary antibody used was Alexa Fluor 594 goat anti-mouse IgG (H + L) at 1:500 (Thermo). Images were taken on a Keyence BZ-X700 fluorescent microscope.

RNA extraction, cDNA synthesis, and qRT-PCR {#s4-11}
-------------------------------------------

Total RNA from zebrafish embryos, tumor tissues, and cells was isolated using the RNeasy Mini or Microkit (QIAGEN). cDNA was reverse transcribed from 200 ng-2µg of total RNA with the RT2 HT First Strand Synthesis kit (QIAGEN). qRT-PCR was performed on an ABI 7900HT using the SYBRGreen Master Mix (BioRad) and a 10 µL total volume in 384 well plates. See [Supplementary file 3](#supp3){ref-type="supplementary-material"} for primer sequences. Delta-delta Ct was calculated, and the calibrator plotted on the far left for every graph. Error bars indicate standard deviation and a student's t-test was performed on normalized Ct replicates to determine significance. The following BioRad qPCR arrays were utilized, M384 Rhabdomyosarcoma for mouse C2C12 cells and H384 Tumor Metastasis (SAB Target List) for Rh30 human RMS cells. Input cDNA was synthesized using the RT2 HT First Strand Synthesis kit (QIAGEN) including a synthetic mRNA as an internal quality control (BioRad). qRT-PCR arrays were run on the BioRad CFX384. Plotted is the fold change above and below the mean gene expression levels from all genes on the array.

Protein extraction and western blots {#s4-12}
------------------------------------

Cells were harvested and lysed in radioimmunoprecipitation assay buffer (RIPA) with cOmplete Mini Protease Inhibitor Cocktail inhibitors (Sigma), and protein levels quantified using Qubit 3.0 Fluorometer (Thermo). Twenty micrograms of protein was denatured and loaded on a 4--20% gradient gel (BioRad), and then transferred to PVDF membranes at 4°C. Membranes were blocked in Casein + 0.1% Tween-20 (Thermo), and incubated overnight at 4°C with the following antibodies with agitation: MYOD monoclonal antibody 5.8A at 1:1000 (Thermo), MYC 71D10 monoclonal antibody at 1:1000 (Cell Signaling), alpha-Tubulin DM1A monoclonal antibody at 1:1000 (Cell Signaling), and MF20 at 1:1000 (Developmental Studies Hybridoma Bank). Goat anti-mouse IgG (H + L)-HRP conjugate and goat anti-rabbit IgG (H + L)-HRP conjugate secondaries were utilized at 1:20,000 (BioRad). Signal was detected using SuperSignal West Pico Chemiluminescent Substrate (Fisher). Membranes were imaged on the BioRad GelDoc XR + and quantification was performed in ImageJ.

Cell culture and transfection {#s4-13}
-----------------------------

C2C12 and Rh30 were a kind gift from Steve Skapek. All cell lines were mycoplasma tested with the MycoAlert Mycoplasma Detection Kit (Lonza) within 6 months of their use and were negative. C2C12 was maintained in DMEM (Gibco) with 10% Fetal Bovine Serum (FBS; Sigma) and 1X Antibiotic-Antimycotic (Gibco) at 37°C in 5% CO~2~. Rh30 were maintained in RPMI-1640 (ATCC) with 10% FBS (Sigma) and 1X Antibiotic-Antimycotic (Gibco) at 37°C in 5% CO~2~. Differentiation media for C2C12s included DMEM (Gibco) with 2% Horse Serum (Sigma) and 10 µg/mL of insulin (Fisher). Cells were transfected with Fugene HD Transfection reagent (Promega) of 3 µL:1 µg of DNA. Cells were selected for 30 days as sub-populations in 1 mg/mL of G418 (Thermo) prior to experiments and were maintained in 1 mg/mL of G418.

Myogenic differentiation in cell culture {#s4-14}
----------------------------------------

C2C12 cells were differentiated by plating 50,000 or 150,000 cells per well on 0.01% porcine/PBS-coated plates (24 wells or six welsl) in growth media + G418. If plating density varied from this it is indicated in the figure. For immunofluorescence C2C12 cells were plated on porcine coated glass coverslips. After 24 hours, cells were washed in 1XPBS, and differentiation media + G418 added. Cells were then fused for 6 days in differentiation media, with fresh media being added every other day. For fusion timepoints, cells were collected and pelleted after incubation in TrypLE Express Enzyme (Fisher), and frozen at −80°C for later total RNA isolation. For immunofluorescence, cells were fixed directly in the well with a 1:1 ratio of 4% paraformaldehyde:media at 37°C for 15 min. Subsequent washing and staining steps are detailed in [@bib27].

Cellular proliferation assays {#s4-15}
-----------------------------

Cells were seeded at 5,000 cells per well for C2C12 and Rh30 in a 24-well plate with four replicates per timepoint. Cells were maintained in GM supplemented with 1 mg/mL of G418 (Gibco) during the course of the experiment. At each timepoint, cells were fixed with 4% PFA for 15 min at room temperature, and stained with 0.0025% crystal violet (Alfa Aesar) in 20% methanol (Sigma) for 15 min. They were then rinsed and crystals were solubilized with 10% Acetic Acid (VWR). Absorbance was read on a plate reader at 595 nm.

Soft agar colony formation assay {#s4-16}
--------------------------------

Colony formation assay strategy was adapted from [@bib6]). A bottom layer of 1.2% noble agar (Difco) in GM was plated with 1 mg/mL of G418 and allowed to solidify, followed by a top layer of 0.6% noble agar in GM with 1 mg/mL of G418 with 5000 cells per well in a six-well plate. Each well was maintained in 100 µL of GM + G418 that was changed three times per week. On day 30, wells were imaged for analysis, with three images being taken at 10X per well and then averaged. Six technical replicates were performed per sub-clonal population. Three biological replicates representing independent sub-clonal populations were included per experiment.

Statistics {#s4-17}
----------

Statistical analysis for survival and tumor incidence curves, and Fisher's exact test, was performed using GraphPad Prism 7.0 c (La Jolla, CA). All other calculations were performed using two-tailed student's t test in Microsoft Excel Version 15.38. Sample sizes are provided in the figures or figure legends.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100004917Cancer Prevention and Research Institute of Texas RP120685-P3 to James F Amatruda.

-   http://dx.doi.org/10.13039/100000043American Association for Cancer Research QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research to Genevieve C Kendall.

-   http://dx.doi.org/10.13039/100001445Alex\'s Lemonade Stand Foundation for Childhood Cancer Young Investigator Grant to Genevieve C Kendall.

-   http://dx.doi.org/10.13039/100006792Hartwell Foundation Postdoctoral Fellowship to Genevieve C Kendall.

-   Ligue National Contre le Cancer to Olivier Delattre.

This project is funded by a grant from Cancer Prevention and Research Institute of Texas (RP120685-P3) to JFA and the Ligue National Contre le Cancer (équipe labellisée). G Kendall is funded by a CPRIT postdoctoral fellowship through the UTSW Cancer Intervention and Prevention Discoveries training program, a QuadW-AACR Postdoctoral Fellowship for Clinical/Translational Sarcoma Research, a Young Investigator Grant from Alex's Lemonade Stand, and a Hartwell Foundation Postdoctoral Fellowship. S Watson was a recipient of a Ph.D. fellowship from Institut Curie. We thank the UTSW Molecular Pathology core and the UTSW Flow Cytometry core for exceptional services and for their expertise. We thank Tim Triche and Javed Khan for sharing RMS genomic data, and members of the Amatruda lab.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Methodology, Writing---original draft, Writing---review and editing.

Investigation, Writing---review and editing.

Data curation, Formal analysis, Investigation, Writing---review and editing.

Investigation, Writing---review and editing.

Investigation, Writing---review and editing.

Formal analysis, Writing---review and editing.

Supervision, Writing---review and editing.

Formal analysis, Supervision, Investigation, Writing---review and editing.

Formal analysis, Supervision, Writing---review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Methodology, Writing---original draft, Project administration, Writing---review and editing.

Human subjects: This study analyzed RNASeq and HuEx data from deidentified patient rhabdomyosarcoma samples. Samples were deidentified and histologic diagnosis and clinical information were compiled. All studies involving human subjects were conducted under a protocol approved by the UT Southwestern Institutional Review Board (approval \# STU 102011-034).

Animal experimentation: UT Southwestern is a registered research facility with the US Department of Agriculture and is committed to comply with the Guide for the Care and Use of Laboratory Animals and all applicable federal, state and local regulations. These pertain to the purchase, transportation, housing and research use of animals. In addition, UT Southwestern is an AAALAC accredited institution that has developed institutional standards for the humane care and use of animals, which are maintained through published policies. Zebrafish research described in this study has been approved and conducted under the oversight of the UT Southwestern Institutional Animal Care and Use Committee (approval \# 2016-101805). UT Southwestern uses the \"Guide for the Care and Use of Laboratory Animals\" when establishing animal research standards.

Additional files {#s6}
================

10.7554/eLife.33800.018

###### Total number of zebrafish analyzed and resulting tumors for Beta Actin, CMV, and ubiquitin driven *PAX3-FOXO1* in wildtype AB or AB/TL strains or *tp53^M214K/M214K^* homozygous mutants.

10.7554/eLife.33800.019

###### Total number of zebrafish analyzed and the mean age of screening for mitfa, fli1, unc503, and mcs (splice acceptor) driven *PAX3-FOXO1*.

10.7554/eLife.33800.020

###### List of oligonucleotide primer sequences.

10.7554/eLife.33800.021

Major datasets {#s7}
--------------

The following dataset was generated:

Triche TSkapek S2018Exon level expression analysis from rhabdomyosarcoma patient tumors.<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114621>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE11462)

The following previously published datasets were used:

Chen XStewart EShelat AQu CBahrami AHatley MWu GBradley C2013Data files for SJRHB RNA-Seq<https://www.ebi.ac.uk/ega/studies/EGAS00001000256>Publicly available at the European Genome-phenome Archive (accession no. EGAD00001000878)

Shern JFChen LChmielecki JWei JSPatidar RRosenberg M2014Genomic sequencing of Pediatric Rhabdomyosarcoma<https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000720.v2.p1>phs000720.v2.p1; Genomic datasets from analysis of human subjects are dbGaP controlled-access data, available to users submitting an approved data access request through the dbGaP Authorized Access System (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login)

Xu LZheng YLiu JRakheja DSingleterry SLaetsch TWShern JF2017Genomic sequencing of Pediatric Rhabdomyosarcoma<https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000720.v2.p1>phs000720.v2.p1; Genomic datasets from analysis of human subjects are dbGaP controlled-access data, available to users submitting an approved data access request through the dbGaP Authorized Access System (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login)
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Decision letter

White

Richard M

Reviewing Editor

Memorial Sloan Kettering Cancer Center

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*PAX3-FOXO1* transgenic zebrafish models identify *HES3* as a mediator of rhabdomyosarcoma tumorigenesis\" for consideration by *eLife*. Your article has been favorably evaluated by Marianne Bronner (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Kendall et al. present data showing the development of a new RMS model in zebrafish. overexpress the human *PAX3-FOXO1* transgene found in alveolar rhabdomyosarcoma under a series of tissue specific and ubiquitous promoters to generate germline transgenic zebrafish that differentially develop tumors at different time points. Transient β-actin driven constructs expressing either *PAX3-FOXO1* or *PAX3* are employed to study the impact on zebrafish embryonic development and individual cell viability. *her3 (HES3* homolog) is identified as a differentially upregulated gene in *PAX3-FOXO1* zebrafish cells. Overexpression of *PAX3-FOXO1* or human *HES3* impairs mature muscle gene expression in zebrafish and overexpression of both increases cell survival. *HES3* overexpression also impairs mammalian muscle development, accelerates human rhabdomyosarcoma cell line proliferation and is found in patient tumors associated with poorer survival. Overall, this is an interesting and timely study that will add to our understanding of this disease. There are several issues raised by the three reviewers that would significantly strengthen the work:

Essential revisions:

1\) The role of p53 and apoptosis in the observed phenotypesa) If *PAX3-FOXO1* results in increased cellular apoptosis (Figure 2E and I) then how do these cells survive to contribute to tumorigenesis? Is this apoptosis p53 dependent, thus the tumors develop only in the context of mutant p53? The authors do not directly address this and should examine apoptosis (e.g. TUNEL staining) in the context of mutant p53. *her3/HES3* may also be contributing as illustrated in Figure 4. Moreover, *PAX3* injected fish had reduced fluorescence compared with GFP or mCherry controls (32% vs. 70%) -- is *PAX3* itself contributing to apoptosis? TUNEL staining or other bona fide apoptosis assays should be included to assess if *her3/HES3* or *PAX3* itself is specifically contributing to cell survival through an anti-apoptotic mechanism.

b\) In Figure 2, the survival curves and representative embryos are convincing for the effects of the translocation. Have you examined the effect of adding in the p53 mutant in terms of survival from these transgenes? What is the onset of the RMS tumors driven by the CMV promoter in the *tp53* mutant background? Tumour presentation of 1.6-19 months of age is a huge range. This should be addressed -- is it due to the different promoters or other factors? Were any fish followed beyond 19 months? If so, did any additional tumors develop? At a minimum, the authors should provide a table that summarizes each transgenic, type of tumor and onset.

2\) The role of *HES3*a) Have you been able to identify any cell lines that have the *PAX3-FOXO1* translocation along with very high levels of *HES3*, and then tried to knock *HES3* down in that context? Does that affect tumorigenic behaviors? This would help give insight into how central *HES3* is, or whether it cooperates with the other genes you identified in Figure 3D (which seems likely). If such cell lines do not exist, could you speculate why *HES3* expression might be disfavored in the development of RMS cell lines?

b\) As the authors point out, *HES3* is likely a transcriptional repressor, which would suggest that it is likely turning off a number of downstream pathways. From their original microarray studies in Figure 3, have they performed any type of analysis to indicate what signaling pathways might represent potential therapeutic targets in this situation? Even though therapeutic targeting is beyond the scope of this paper, it would be useful for the field to know what things they might go after in *HES3*+ tumors, and these pathways would be useful to bring up in the Discussion.

3\) The effect of *PAX3-FOXO1* on muscle biology and embryo developmenta) *PAX3-FOXO1* is shown to be more toxic to developing embryos than *PAX3* alone (Figure 2H). For Figure 3 microarrays on whole embryos, could the gene expression differences be more indicative of cell populations lost in *PAX3-FOXO1*-expressing embryos? Do we know that the actual cells overexpressing either of these constructs are being assessed for alterations in *HES3* expression (i.e. is this a cell autonomous effect?).

b\) Given that *PAX3-FOXO1* makes cells \"sick\" (Figure 2) and the fusion exerts some of its effects through *HES3*, could the decreased ability of myofibers to fuse with *HES3* overexpression in Figure 5 be nonspecific (i.e. are the cells unable to engage a specific differentiation program, or is this effect found with mis-expression of other, perhaps many, transcription factors?)

c\) Along the same lines, while qPCR data suggests that *PAX3-FOXO1* zebrafish do not have muscle maturation by demonstrating low myoD expression levels, this is difficult to interpret in the context of mosaic animals and post-translational modifications of myoD. Thus, the zebrafish qPCR data should be supplemented with myoD immunofluorescence studies. Similarly, studies of myoD at the protein level (e.g. myoD and phospho-myoD by Western blot) should be done in the murine cell lines.

10.7554/eLife.33800.032

Author response

> Essential revisions:
>
> 1\) The role of p53 and apoptosis in the observed phenotypesa) If PAX3-FOXO1 results in increased cellular apoptosis (Figure 2E and I) then how do these cells survive to contribute to tumorigenesis? Is this apoptosis p53 dependent, thus the tumors develop only in the context of mutant p53? The authors do not directly address this and should examine apoptosis (e.g. TUNEL staining) in the context of mutant p53. her3/HES3 may also be contributing as illustrated in Figure 4. Moreover, PAX3 injected fish had reduced fluorescence compared with GFP or mCherry controls (32% vs. 70%) -- is PAX3 itself contributing to apoptosis? TUNEL staining or other bona fide apoptosis assays should be included to assess if her3/HES3 or PAX3 itself is specifically contributing to cell survival through an anti-apoptotic mechanism.

These questions are addressed in the experiments presented in new Figure 2---figure supplements 1-2. *PAX3-FOXO1* induces significant apoptosis in a wildtype zebrafish genetic background with both the BetaActin-*PAX3FOXO1* and CMV-*PAX3FOXO1* expression constructs. However, in the BetaActin-*PAX3FOXO1* model a sufficient number of cells escape to generate tumors (Figure 1B, F). In the new Figure 2---figure supplement 1, we explored whether this was true for the CMV-*PAX3FOXO1* model which differs from BetaActin-*PAX3FOXO1* in that it requires a *p53* mutation to generate RMS. We found that when injecting mosaic CMV-*PAX3FOXO1* into wildtype or *p53* mutant zebrafish that *PAX3-FOXO1*+ cells were more abundant in the *p53* mutant background. This was not true for other injected groups including the GFP controls and GFP-*PAX3*.

We next performed TUNEL to test whether this abundance of *PAX3-FOXO1*+ cells was due to a dysregulation of *p53*-mediated apoptosis. We found that in control GFP injected groups and *PAX3* injected groups there was no significant difference in the number of cells undergoing apoptosis when comparing wildtype and *p53* mutant zebrafish. However, there was a trend of increased apoptosis in the context of *PAX3* injections in wildtype zebrafish versus *p53* mutant zebrafish. These experiments underscored that *PAX3* is contributing in-part to an increase in embryonic apoptosis, but that the observed effect does not account for the entire spectrum of apoptosis that is induced by the *PAX3-FOXO1* fusion. In *PAX3-FOXO1* injected groups there was a significant decrease in apoptosis in *p53* mutant zebrafish as compared to their wildtype counterparts. Therefore, in the CMV-*PAX3FOXO1* model, the *p53* mutation is a sensitizer that allows these cells to survive and thus generate tumors later on. This model is outlined in Figure 2---figure supplement 2. This may represent a unique necessity in animal models; as both fusion-positive RMS vertebrate models of the disease (zebrafish presented here, and the *Pax3-Foxo1* mouse model), require that *p53* is mutant or lost for the generation of disease.

We detailed in Figure 4---figure supplement 1 how overexpression of human *HES3* contributed to the apoptosis phenotype in our CMV-*PAX3FOXO1* injected zebrafish embryonic model. We co-injected zebrafish with the following experimental design: 1) *HES3*+control, 2) *PAX3-FOXO1*+control, and 3) *PAX3-FOXO1*+*HES3*. Consistent with our previous data in the BetaActin-*PAX3FOXO1* model (Figure 4D-F) *HES3* overexpression allowed for GFP-*PAX3FOXO1*+ cells to persist. This trend was not true for GFP controls, *HES3* alone, or *PAX3-FOXO1* injected alone. We then performed TUNEL assays to determine if apoptotic inhibition was accounting for this increase in *PAX3-FOXO1*+ cells. This is not the case as *PAX3FOXO1*+*HES3* does not ameliorate the apoptosis phenotype. This model is detailed in Figure 4---figure supplement 2. However, these experiments did confirm that *PAX3-FOXO1* significantly increases apoptosis in the context of the CMV promoter, and that *HES3* alone does not.

> b\) In Figure 2, the survival curves and representative embryos are convincing for the effects of the translocation. Have you examined the effect of adding in the p53 mutant in terms of survival from these transgenes? What is the onset of the RMS tumors driven by the CMV promoter in the tp53 mutant background? Tumour presentation of 1.6-19 months of age is a huge range. This should be addressed -- is it due to the different promoters or other factors? Were any fish followed beyond 19 months? If so, did any additional tumors develop? At a minimum, the authors should provide a table that summarizes each transgenic, type of tumor and onset.

We have performed the proposed survival experiment in Figure 2---figure supplement 1B. We found that injected CMV-*PAX3FOXO1* significantly decreased survival over three days of life in *p53* mutant embryos as compared to a wildtype background. CMV-*PAX3FOXO1* survival in a *p53* mutant background was also significantly different from *PAX3* injected into a *p53* or wildtype background, indicating that the observed activity is due in large part to the oncogenic fusion. These data suggest that *p53* mutants are unable to mount the appropriate response to an oncogenic insult, thus facilitating a more amenable environment for *PAX3-FOXO1*+ cellular survival and subsequent tumor development in those embryos that do survive.

The tumor incidence curve for RMS tumors in the *p53* mutant background is presented in Figure 1G. The tumor spectrum, onset, and details for all presented promoters and collected zebrafish tumors are presented in Supplementary files 1 and 2. We agree that the tumor spectrum and onset vary between the BetaActin-*PAX3FOXO1* and CMV-*PAX3FOXO1* models and attribute this discrepancy to being a mosaic model in which *PAX3-FOXO1* is under the control of different promoters in different genetic contexts. Every mosaic injection encompasses a different cellular context in which *PAX3-FOXO1* is being exposed to developmental cues. We have revised the text accordingly.

> 2\) The role of HES3a) Have you been able to identify any cell lines that have the PAX3-FOXO1 translocation along with very high levels of HES3, and then tried to knock HES3 down in that context? Does that affect tumorigenic behaviors? This would help give insight into how central HES3 is, or whether it cooperates with the other genes you identified in Figure 3D (which seems likely). If such cell lines do not exist, could you speculate why HES3 expression might be disfavored in the development of RMS cell lines?

We agree that such experiments would delineate how essential *HES3* is to RMS cell survival. To identify HES3 expressing cell lines we have surveyed a panel of fusion-positive and fusion-negative RMS cell lines for *HES3* mRNA expression and HES3 protein expression. *HES3* mRNA is expressed at low levels and *HES3* protein is undetectable (data not shown). During normal development, *HES3* inhibits differentiation of neural stem cell populations. We discovered *her3/HES3's* importance in the disease in a dynamic vertebrate developmental model system and have shown that *HES3* marks a less differentiated cellular population. We suspect *HES3* is lost during cell culture passaging over time due the artificial nature of culture conditions and the lack of developmental cues. Therefore, we will be exploring alternative models for studying *HES3* in culture systems including 3D cultures or primary patient xenografts. We anticipate 3D cultures and patient xenografts will more faithfully recapitulate *HES3*'s role in the development of RMS, will be a useful tool to identify novel markers of the disease, and will assess how stringently these models recapitulate each other and the patient.

> b\) As the authors point out, HES3 is likely a transcriptional repressor, which would suggest that it is likely turning off a number of downstream pathways. From their original microarray studies in Figure 3, have they performed any type of analysis to indicate what signaling pathways might represent potential therapeutic targets in this situation? Even though therapeutic targeting is beyond the scope of this paper, it would be useful for the field to know what things they might go after in HES3+ tumors, and these pathways would be useful to bring up in the Discussion.

We thank the reviewers for this suggestion. To address potential druggable targets we have analyzed RMS primary patient tumors and identified genes that are up and down-regulated in the context of *HES3* overexpression (Figure 7E). This analysis has identified a subset of druggable molecular targets with therapeutic implications; namely, the identification of *FGFR4, PARP1*, and *ALK* as being significantly overexpressed in *HES3*+ RMS. There are also targets that are downregulated which may be supplemented such as *DNAJC6*. We anticipate future studies will define the mechanistic contributions of these targetable genes as therapeutic strategies.

> 3\) The effect of PAX3-FOXO1 on muscle biology and embryo developmenta) PAX3-FOXO1 is shown to be more toxic to developing embryos than PAX3 alone (Figure 2H). For Figure 3 microarrays on whole embryos, could the gene expression differences be more indicative of cell populations lost in PAX3-FOXO1-expressing embryos? Do we know that the actual cells overexpressing either of these constructs are being assessed for alterations in HES3 expression (i.e. is this a cell autonomous effect?).

In Figure 3 the microarray was performed on RNA isolated from FACS sorted GFP positive cells from injected zebrafish embryos. Therefore, we are confident the observed expression changes are cell-autonomous events and that *PAX3-FOXO1* is upregulating *her3* expression within the same cells.

> b\) Given that PAX3-FOXO1 makes cells \"sick\" (Figure 2) and the fusion exerts some of its effects through HES3, could the decreased ability of myofibers to fuse with HES3 overexpression in Figure 5 be nonspecific (i.e. are the cells unable to engage a specific differentiation program, or is this effect found with mis-expression of other, perhaps many, transcription factors?)

*HES3* is well tolerated in our overexpression systems including zebrafish models and stable cell lines. This indicates that *HES3* exerts a specific effect when it comes to dysregulating the engagement of myogenic differentiation. C2C12 or other myoblast fusion assays are established assays to determine genes that interfere with the fusion process. Such assays can distinguish between transcription factors or co-factors that inhibit or promote fusion. This has been the basis for high-throughput screens to identify specifically transcription factors that act as modifiers of the differentiation process (1). This strategy identified a subset of transcription factors that enhanced myogenic fusion, inhibited myogenic fusion, and a number that had no effect suggesting a specificity to the results. We have complemented our C2C12 mouse myoblast data with zebrafish developmental data in which *HES3* overexpression inhibits myogenesis in vivo (Figure 3C). We believe that *HES3* does not make the embryos sick, but rather likely promotes a modified differentiation state, and that this differentiation state is more capable of tolerating the oncogenic insult of the *PAX3-FOXO1*+ fusion. Therefore, since C2C12 myoblasts are healthy with *HES3* overexpression, and are capable of differentiating in some capacity after fusion induction, our interpretation is that *HES3* overexpression is engaging and inhibiting the differentiation program. The mechanism for this inhibition is likely indicative of *HES3*'s in vivo activity in combination with *PAX3-FOXO1*.

> c\) Along the same lines, while qPCR data suggests that PAX3-FOXO1 zebrafish do not have muscle maturation by demonstrating low myoD expression levels, this is difficult to interpret in the context of mosaic animals and post-translational modifications of myoD. Thus, the zebrafish qPCR data should be supplemented with myoD immunofluorescence studies. Similarly, studies of myoD at the protein level (e.g. myoD and phospho-myoD by Western blot) should be done in the murine cell lines.

In Figure 4C expression of *PAX3-FOXO1, HES3*, and *PAX3-FOXO1*+*HES3* had no significant effect on zebrafish *myod* or *myog* expression as compared to injected controls. We tested numerous antibodies that could potentially recognize zebrafish myoD, but no antibodies cross-reacted or faithfully recapitulated its known embryonic expression patterns. Therefore, in Figure 4B we have added a panel indicating that our mosaic injected transgenes do overlay with myosin protein, one of the muscle genes assayed in Figure 4C.

This data was supplemented with MyoD protein levels in C2C12 cells overexpressing HES3. We found that there was no difference in MyoD expression during the early initiation of differentiation; however, there was a trend towards decreased MyoD expression during terminal differentiation (Figure 5---figure supplements 1-2). Therefore, we concluded that in zebrafish and mammalian systems HES3 is not acting as a dominant negative on MyoD, but perhaps is inhibiting differentiation via engaging a different mechanism.

We have found that observations made from mosaic zebrafish are predictive of results from fluorescent cell populations that are sorted from embryos. For example, in Figure 3D GFP-*PAX3FOXO1*+ cells were FACS sorted from developing embryos, and *her3* exhibited a 21 fold up-regulation of expression. In Figure 3E we utilized zebrafish embryos injected with mosaic GFP-*PAX3FOXO1* and the entire embryo was implemented for RNA isolation and qRT-PCR of *her3* expression levels. In this context, *her3* exhibited \~5 fold increase in expression as compared to controls. Therefore, the mosaic expression system is sufficient to identify meaningful differences, but the effect might be muted in comparison to cell populations that are FACS sorted.
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